Advertisement

Boston cancer-focused biotech startup Tesaro Inc. has landed an exclusive licensing deal with Amgen Inc., in which the Boston company will hold rights to Amgen’s Anaplastic Lymphoma Kinase (ALK) technology.

Tesaro intends to apply Amgen’s ALK tech to develop treatments for non-small cell lung cancer marked by ALK-positive tumors. ALK, expressed abnormally, may also be linked to lymphoma and neuroblastoma.

SOURCE

Advertisement
Advertisement